Treatment of elevated metabolite levels using nanocarriers

A nano-carrier system comprising a functional RNA encapsulated inside an Enterobacteria phage MS2 (MS2) virus-like particle (VLP), wherein the functional RNA comprises an RNA riboswitch and a packing sequence, and said riboswitch maintains its functionality while being encapsulated inside said VLP and is protected from nuclease degradation in vivo.

A method of treating a metabolic disorder characterized by elevated metabolite levels in a subject, or of inhibiting or delaying the formation of metabolite assemblies in said subject, the method comprising administering to the subject a pharmaceutical composition comprising a nano-carrier system, wherein the nano-carrier system comprises a virus-like particle (VLP) and a metabolite-specific functional RNA encapsulated inside the VLP, wherein the functional RNA maintains its ability to selectively bind the metabolite while being encapsulated inside said VLP, and is protected from nuclease degradation in vivo.

A method of reducing the levels of a metabolite in a food product, comprising contacting the food product or a precursor thereof with a chelating composition comprising a nano-carrier system, the nano-carrier system comprising a virus-like particle (VLP) and a metabolite-specific functional RNA encapsulated inside the VLP, wherein the functional RNA maintains its ability to selectively bind the metabolite while being encapsulated inside said VLP, and is protected from nuclease degradation in vivo.

A nano-carrier system comprising a virus-like particle (VLP) and a functional RNA encapsulated inside said VLP, wherein said VLP is configured to protect said functional RNA from nuclease degradation in vivo, and wherein said functional RNA maintains its functionality while being encapsulated inside said VLP.